Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference

"Our primary objective this year is the advancement of our clinical programs with fostamatinib, which are targeted for early 2016 readouts, moving the company towards a potential NDA filing," said Mr. Rodriguez. "Additionally, we are pursuing partnerships for some of our active preclinical projects," he added.

http://ift.tt/1xULBWu